Effect of hyperbaric oxygen therapy on cognitive function and serum Humanin level in patients with Alzheimer′s disease

doi:10.3877/cma.j.issn.2095-655X.2019.02.003

Abstract

Abstract:

Objective

To investigate the effect of hyperbaric oxygen (HBO) on cognitive function and serum Humanin expression in patients with Alzheimer′s disease (AD).

Methods

From June 2015 to June 2017, 72 patients with mild to moderate AD admitted to the Neurology of Taian Central Hospital were selected. The patients were divided into control group and HBO treatment group by random number table method, each group with 36 patients. The control group was given conventional treatments and HBO treatment group was treated with HBO based on the conventional treatments, both groups were treated for 2 months. Mini-mental state examination (MMSE) scores, Montreal Cognitive Assessment (MoCA)scores and serum levels of Humanin in the two groups were compared before and after treatment.

Results

Before treatment, the MMSE score, MoCA score and serum Humanin level of the control group were (15.35±2.12) points, (17.08±2.73) points, (147.2±39.6) ng/L, respectively. The MMSE score, MoCA score and serum Humanin level in the HBO treatment group were (15.29±2.43) points, (17.16±2.61) points, (141.8±41.3) ng/L, respectively, there were no significant differences between the two groups (t=0.11, -0.13, 0.57, all P>0.05). After treatment, the MMSE score, MoCA score and serum Humanin level of the control group were (18.57±3.59)points, (20.46±3.07)points, (180.9±48.1)ng/L, which were lower than those in the HBO treatment group [(20.68±2.97)points, (22.74±3.28)points, (216.5±52.9)ng/L, respectively], the differences were significant (t=-2.72, -3.05, -2.99, all P<0.01). Serum Humanin level was positively correlated with MMSE score (r=0.628, P<0.05), and MoCA score (r=0.691, P<0.05).

Conclusion

Hyperbaric oxygen can improve the cognitive function of AD patients, and the mechanism may be related to the increased serum levels of Humanin.

Key words: Alzheimer disease, Hyperbaric oxygen, Cognition, Humanin

Yuzhen Xu, Qian Wang, Min Shan, Tao Wang, Weixia Yang, Xinping Zhang. Effect of hyperbaric oxygen therapy on cognitive function and serum Humanin level in patients with Alzheimer′s disease[J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(02): 83-86.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2019.02.003

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I02/83

Figures/Tables 2

References 22

[1]	Hung AS, Liang Y, Chow TC, et al. Mutated tau，amyloid and neuroinflammation in Alzheimer disease-A brief review[J]．Prog in Histochem Cytochem，2016，51(1):1-8.
[2]	Wolters FJ, Koudstaal PJ, Hofman A，et al.Serum apolipoprotein E is associated with long-term risk of Alzheimer′s disease：the rotterdam study[J]．Neurosci Lett，2016(617):139-142.
[3]	Kumar A, Singh A, Ekavali.A review on Alzheimer′s disease pathophysiology and its management：an update[J]．Pharmacol Rep，2015，67(2):195-203.
[4]	杨鹏，岳阳，周效宝，等．阿尔茨海默病患者脑电功率值特征分析[J/CD]．中华诊断学电子杂志，2015，3(1):36-40.
[5]	Boussi-Gross R, Golan H, Volkov O，et al.Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy[J]．Neuropsychology，2015，29(4):610-621.
[6]	Matsuoka M. Protective effects of Humanin and calmodulin-like skin protein in Alzheimer′s disease and broad range of abnormalities[J]．Mol Neurobiol，2015，51(3):1232-1239.
[7]	Association AP.Diagnostic and statistical manual of mental disorders (DSM-5®)[M] .Washington：American Psychiatric Pub，2013：611-614.
[8]	Dubois B, Feldman HH, Jacova C，et al.Research criteria for the diagnosis of Alzheimer′s disease：revising the NINCDS-ADRDA criteria[J]．Lancet Neurol，2007，6(8):734-746.
[9]	李伟，肖世富．阿尔茨海默病诊断标准的演变及评价[J/CD]．中华诊断学电子杂志，2015，3(2):114-117.
[10]	贾阳娟，韩凝，王美蓉，等．MoCA与MMSE在急性缺血性卒中后认知障碍评估中的应用[J]．中华行为医学与脑科学杂志，2017，26(1):46-50.
[11]	Mittal K, Katare DP.Shared links between type 2 diabetes mellitus and Alzheimer′s disease：A review[J]．Diabetes Metab Syndr，2016，10(2 Suppl 1):S144-S149.
[12]	Alzheiner′s Association.2017 Alzheimer′s disease facts and figures[J]．Alzheimer′s & Dementia，2017，13(4):325-373.
[13]	Shapira R, Solomon B, Efrati S，et al. Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation[J]．Neurobiol Aging，2018(62):105-119.
[14]	Zhao BS, Pan YY, Wang ZY，et al.Hyperbaric oxygen pretreatment improves cognition and reduces hippocampal damage via p38 mitogen-activated protein kinase in a rat model[J]. Yonsei Med J，2017，58(1):131-138.
[15]	王晖霖，唐建梅．高压氧对阿尔茨海默病患者血清雌激素水平的影响[J]．中国医药导报，2011，8(5):26-28.
[16]	高聚，姜华，宛丰，等．高压氧联合多奈哌齐治疗阿尔茨海默病的疗效及对血清内皮素-1的影响[J]. 神经损伤与功能重建，2017，12(3):269-271.
[17]	Gong Z, Tas E, Muzumdar R．Humanin and age-related diseases：a new link？[J]．Front Endocrinol (Lausanne)，2014(5):210.
[18]	Zhang XP, Zhang QL, Du YF.A novel rattin expression in the brain of the rat model of patients′ vascular dementia[J]．J Neurol Sci Neurophysiol，2013，30(2):249-256.
[19]	Liu W, Zhang XP, Yang DL，et al.Humanin attenuated the change of voltage-dependent potassium currents in hippocampal neurons induced by anoxia[J]．CNS Neurosci Ther，2014，20(1):95-97.
[20]	Han K, Jia N, Zhong Y, et al. S14G-humanin alleviates insulin resistance and increases autophagy in neurons of APP/PS1 transgenic mouse[J]．J Cell Biochem，2018，119(4):3111-3117.
[21]	Alam MP, Bilousova T, Spilman P，et al.A small molecule mimetic of the humanin peptide as a candidate for modulating NMDA-induced neurotoxicity[J]．ACS Chem Neurosci，2018，9(3):462-468.
[22]	Cui AL, Zhang YH, Li JZ, et al. Humanin rescues cultured rat cortical neurons from NMDA-induced toxicity through the alleviation of mitochondrial dysfunction[J]．Drug Des Devel Ther，2017(11):1243-1253.

组别	例数	MMSE		MoCA
组别	例数	治疗前	治疗2个月后	治疗前	治疗2个月后
对照组	36	15.35±2.12	18.57±3.59	17.08±2.73	20.46±3.07
治疗组	36	15.29±2.43	20.68±2.97	17.16±2.61	22.74±3.28
t值	?	0.11	－2.72	－0.13	－3.05
P值	?	0.911	0.008	0.899	0.003

组别	例数	MMSE		MoCA
组别	例数	治疗前	治疗2个月后	治疗前	治疗2个月后
对照组	36	15.35±2.12	18.57±3.59	17.08±2.73	20.46±3.07
治疗组	36	15.29±2.43	20.68±2.97	17.16±2.61	22.74±3.28
t值	?	0.11	－2.72	－0.13	－3.05
P值	?	0.911	0.008	0.899	0.003

组别	例数	治疗前	治疗2个月后
对照组	36	147.21±39.63	180.97±48.10
治疗组	36	141.86±41.32	216.58±52.95
t值	?	0.57	－2.99
P值	?	0.573	0.004

组别	例数	治疗前	治疗2个月后
对照组	36	147.21±39.63	180.97±48.10
治疗组	36	141.86±41.32	216.58±52.95
t值	?	0.57	－2.99
P值	?	0.573	0.004

Please choose a citation manager

Content to export